Previous close | 145.23 |
Open | 142.66 |
Bid | 139.93 x 100 |
Ask | 140.07 x 200 |
Day's range | 138.17 - 145.74 |
52-week range | 62.55 - 170.47 |
Volume | |
Avg. volume | 3,874,898 |
Market cap | 53.665B |
Beta (5Y monthly) | 1.54 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna stock is trading sideways despite a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?